tradingkey.logo

Bausch + Lomb Corp

BLCO
查看详细走势图
16.950USD
+0.050+0.30%
收盘 12/19, 16:00美东报价延迟15分钟
6.00B总市值
亏损市盈率 TTM

Bausch + Lomb Corp

16.950
+0.050+0.30%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+0.30%

5天

-0.24%

1月

+16.41%

6月

+44.50%

今年开始到现在

-6.15%

1年

-5.83%

查看详细走势图

TradingKey Bausch + Lomb Corp股票评分

单位: USD 更新时间: 2025-12-19

操作建议

Bausch + Lomb Corp当前公司基本面数据相对稳定,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名74/208位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价17.15。中期看,股价处于上升通道。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Bausch + Lomb Corp评分

相关信息

行业排名
74 / 208
全市场排名
175 / 4582
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 14 位分析师
持有
评级
17.154
目标均价
+3.59%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Bausch + Lomb Corp亮点

亮点风险
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
业绩高增长
公司营业收入稳步增长,连续3年增长27.15%
估值合理
公司最新PE估值-19.69,处于3年历史合理位
机构加仓
最新机构持股42.63M股,环比增加0.03%
霍华德·马克斯持仓
明星投资者霍华德·马克斯持仓,最新持仓市值3.25M

Bausch + Lomb Corp新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Bausch + Lomb Corp简介

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
公司代码BLCO
公司Bausch + Lomb Corp
CEOSaunders (Brenton L)
网址https://ir.bausch.com/

常见问题

Bausch + Lomb Corp(BLCO)的当前股价是多少?

Bausch + Lomb Corp(BLCO)的当前股价是 16.950。

Bausch + Lomb Corp的股票代码是什么?

Bausch + Lomb Corp的股票代码是BLCO。

Bausch + Lomb Corp股票的52周最高点是多少?

Bausch + Lomb Corp股票的52周最高点是18.553。

Bausch + Lomb Corp股票的52周最低点是多少?

Bausch + Lomb Corp股票的52周最低点是10.450。

Bausch + Lomb Corp的市值是多少?

Bausch + Lomb Corp的市值是6.00B。

Bausch + Lomb Corp的净利润是多少?

Bausch + Lomb Corp的净利润为-317.00M。

现在Bausch + Lomb Corp(BLCO)的股票是买入、持有还是卖出?

根据分析师评级,Bausch + Lomb Corp(BLCO)的总体评级为持有,目标价格为17.154。

Bausch + Lomb Corp(BLCO)股票的每股收益(EPS TTM)是多少

Bausch + Lomb Corp(BLCO)股票的每股收益(EPS TTM)是-0.862。
KeyAI